28226-20-2

Usage

Uses

Used in Pharmaceutical Research:
2-(2,5-Dimethoxyphenylamino)ethanol is used as an intermediate in pharmaceutical research for the development of new drugs and medications. Its unique chemical properties make it a valuable compound for creating innovative pharmaceutical products.
Used in Organic Synthesis:
2-(2,5-Dimethoxyphenylamino)ethanol is used as an intermediate in organic synthesis, allowing for the creation of various chemical compounds and materials.
Used in Laboratory and Research:
2-(2,5-Dimethoxyphenylamino)ethanol is used for various laboratory and research purposes due to its unique chemical properties, enabling scientists to explore new avenues in chemical research and development.

Upstream product

• 624-76-0 Iodoethanol 
• 102-56-7 2,5-dimethoxyaniline 
• 540-51-2 2-bromoethanol 

Downstream Products

• 258524-53-7 4-benzoyl-6-hydroxy-3,4-dihydro-2H-1,4-benzoxazine 
• 26021-57-8 3,4-dihydro-6-hydroxy-1,4(2H)-benzoxazine 

Relevant academic research and scientific papers

One-pot synthesis of unsymmetrical N-heterocyclic carbene ligands from N-(2-iodoethyl)arylamine salts

Image Presented An approach that provides symmetrical, unsymmetrical, and asymmetric N-heterocyclic carbene (NHC) ligands is reported. Reaction of iodoethanol with aniline provides N-(2-iodoethyl)arylamine salts that are then converted to the corresponding iodide. Reaction with aliphatic or aromatic amines followed by triethyl orthoformate was used to provide 26 different NHC ligands.

Synthesis of oxypropanolamine derivatives of 3,4-dihydro-2H-1,4- benzoxazine, β-adrenergic affinity, inotropic, chronotropic and coronary vasodilating activities

A series of oxypropanolamine derivatives of 3,4-dihydro-2H-1,4- benzoxazine were synthesized and evaluated for inotropic, chronotropic and coronary vasodilating activities in the canine heart, affinity to β1- adrenergic receptor in turkey erythrocytes and affinity to the β2- adrenergic receptor in the rat lung. Among these compounds, 4-acetyl-6-(3- tert-butylamino-2-hydroxy)propoxy-3,4-dihydro-2H-1,4-benzoxazine showed 2.1- fold more potent affinity to the β1 receptor than propranolol and 7-(3- tert-butylamino-2-hydroxy)propoxy-N-butyryl-3,4-dihydro-2H-1,4-benzoxazine showed 2.5-fold more potent affinity to the β2 receptor and furthermore 4 386-fold more potent selectivity to the β2 receptor than propranolol. In addition, 4-acetyl-6-[3-(3,4-dimethoxybenzyl)amino-2-hydroxy]propoxy-3,4- dihydro-2H-1,4-benzoxazine showed 1.1-fold more potent affinity to the β1 receptor than propranolol and also 1 147-fold more potent selectivity to the β1 receptor. With a few exceptions, negative inotropic and chronotropic actions of these compounds were dependent on the size of the 4-substituent obeying the order: unsubstituted 1-adrenoceptor nor coronary vasodilator action related with affinity to β2-adrenoceptor were observed. 4-acetyl-7- [3-(3,4-dimethoxybenzyl)amino-2-hydroxy]propoxy-3,4-dihydro-2H-1,4- benzoxazine exerted potent positive inotropic, chronotropic and coronary vasodilating actions. The inotropic and chronotropic actions of the latter compound may be attributed to the release of intrinsic catecholamines, as concluded by the absence of β1-adrenoceptor affinity and disappearance of activity in the presence of a β-blocker.